Vertex's Incivek wins FDA approval for HCV
This article was originally published in Scrip
Executive Summary
With the 23 May approval of its protease inhibitor Incivek (telaprevir) – with Wall Street never doubting it would achieve the US FDA's blessing –Vertex is betting that the drug's value in clearing hepatitis C virus (HCV) will make its higher price tag worth it for patients, prescribers and, most importantly, insurers.